首页> 外文期刊>Medical oncology >Angioimmunoblastic T-cell lymphoma: The effect of initial treatment and microvascular density in 31 patients
【24h】

Angioimmunoblastic T-cell lymphoma: The effect of initial treatment and microvascular density in 31 patients

机译:血管免疫母细胞性T细胞淋巴瘤:初治和微血管密度对31例患者的影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The objectives of this study are to explore the clinical features and treatment outcomes and to investigate the correlation between microvessel density (MVD) and survival in patients with angioimmunoblastic T-cell lymphoma (AITL). We retrospectively analyzed clinical and follow-up data of 31 patients treated in two hospitals during 1995-2009 histologically proven AITL. We also assessed MVD in the lump of 31 previously untreated patients using α-CD34 immunohistochemical staining. The median age of the 31 patients was 48 years, eighty percent of the patients were in an advanced stage. 67.7% of them had B symptoms, with the follow-up of 2-13 years, the 5-year overall survival rate was 25.8%. The response rates (RR) of CHOP group and COP (cyclophosphamide, vincristine and prednisolone) group are 76.5 and 75%, respectively, which is no significant difference (P = 0.894). RR did not differ whether chemotherapy regimens contained anthracycline or not. The 3-year PFS rate for patients who received COP and CHOP regimen was 25.4 and 35.3% (P = 0.562), while 5-year OS rates were 25.0 and 29.4%, respectively (P = 0.667). The median PFS for patients with high MVD and low MVD were 15.1 and 30.0 months (P = 0.048), while the median OS were 20 and 45 months, respectively (P = 0.038). Patients who were sensitive to initial chemotherapy COP regimen have the similar therapeutic effect to CHOP regimen. Patients with high MVD measured in the microenvironment had worse PFS and OS than AITL patients with low expression.
机译:这项研究的目的是探讨临床特征和治疗结果,并探讨血管免疫母细胞性T细胞淋巴瘤(AITL)患者的微血管密度(MVD)与生存之间的相关性。我们回顾性分析了1995-2009年经组织学证实的AITL在两家医院接受治疗的31例患者的临床和随访数据。我们还使用α-CD34免疫组织化学染色评估了31名先前未接受治疗的患者的MVD。 31名患者的中位年龄为48岁,其中80%处于晚期。其中67.7%患有B症状,随访2-13年,其5年总生存率为25.8%。 CHOP组和COP(环磷酰胺,长春新碱和泼尼松龙)组的缓解率(RR)分别为76.5和75%,差异无统计学意义(P = 0.894)。无论化疗方案是否包含蒽环类药物,RR均无差异。接受COP和CHOP方案的患者的3年PFS率分别为25.4%和35.3%(P = 0.562),而5年OS率分别为25.0%和29.4%(P = 0.667)。高MVD和低MVD患者的中位PFS分别为15.1和30.0个月(P = 0.048),而中位OS分别为20和45个月(P = 0.038)。对初始化疗COP方案敏感的患者具有与CHOP方案相似的治疗效果。在微环境中测得的MVD高的患者的PFS和OS比低表达的AITL患者更差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号